# VANI earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VANI) · [Earnings tab](https://www.lopjlb.com/stock/VANI?tab=earnings)

Updated: 2026-08-12T05:26:09

Quarters analyzed: 8

## Cross-quarter narrative

Across the eight quarterly calls, Second Sight’s narrative shifted from a dual‑product focus toward an exclusive Orion platform strategy. Early 2018 calls highlighted modest Argus II sales, emerging Orion feasibility work, and cash‑runway concerns. By late 2018 the company began reallocating $3 M of operating savings and secured a $34.6 M rights offering to fund Orion, while Argus II volumes fell and technical issues with next‑gen externals surfaced. 2019 calls emphasized positive 12‑month Orion feasibility results, advancing FDA discussions and CMS breakthrough‑device pathway, yet regulatory path uncertainty (PMA vs HDE), enrollment delays, and reimbursement gaps persisted. The COVID‑19 pandemic introduced a new delay for FLORA 20 validation and heightened financial risk. Throughout, recurring themes of regulatory ambiguity, reimbursement variability, cash‑runway pressure, and clinical enrollment challenges remained, while Orion’s data quality and market interest improved. The timeline reflects a transition from Argus‑centric revenue to an Orion‑centric R&D and financing model, with mixed milestone execution and evolving risk profile.

## Latest CallCard · Q4

Second Sight reported positive 12‑month Orion study results, secured CE mark and conditional FDA approval for Argus 2s wearables, but pushed the IDE filing to H1 2021 and paused FLORA 20 validation due to COVID‑19.

**Guidance:** lowered — IDE filing moved from year‑end 2020 to first half 2021, reflecting a more conservative timeline.

**Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3

Prepared remarks emphasized continued execution, progress on R&D and regulatory discussions, and confidence in the team despite leadership transition.

### Demand visibility

Seeking clarity on FDA safety endpoint and reimbursement pathways.

Management discussed agreement on efficacy endpoint, ongoing FDA negotiations on safety parameters, and meetings with CMS and private payers; analysts asked about PMA vs HDE route.

### Margins / costs

R&D expenses rising due to Orion prototype production.

R&D expense $4.1 M in Q4 2019 versus $2.4 M in Q4 2018, driven by prototype costs; future R&D expected to increase with additional personnel and validation work.

### Capital allocation

Focus on R&D and clinical development; reverse split for Nasdaq compliance.

No specific financing disclosed; future financing plans will be discussed later; 1:8 reverse stock split executed in January to remain Nasdaq‑compliant.

### Milestones

- **Orion Early Feasibility Study 6th subject 12‑month milestone** [on_track]: Sixth subject reached 12‑month testing with positive results across key measures.
- **FLORA 20 validation** [at_risk]: Validation suspended due to COVID‑19 social distancing protocols.
- **IDE filing for next‑gen Orion implant** [delayed]: Now expected in first half 2021 instead of year‑end 2020 due to ongoing FDA negotiations.
- **Conditional FDA approval for Argus 2s wearables** [delivered]: Approval received; limited market introduction planned.
- **CE Mark for Argus 2s** [delivered]: CE mark obtained, enabling EU marketing.
- **CMS reimbursement discussions** [on_track]: Productive meeting with CMS national coverage team to define Medicare pathway.
- **Legislative proposals H.R. 5333 and S.2326** [new]: Bills introduced to address coverage for breakthrough devices like Orion.
- **CEO transition** [new]: Will McGuire departing; will join board; Greg Williams acting CEO.

### Fears / risks

- **Regulatory risk**: Uncertainty around FDA agreement on safety endpoint for the pivotal Orion trial.
- **COVID‑19 impact**: Pandemic has halted FLORA 20 validation and may affect future trial timelines.
- **Reimbursement risk**: Need to secure Medicare and private payer coverage for Orion upon regulatory approval.
- **Market adoption risk**: Limited initial rollout of Argus 2s wearables could slow feedback and broader adoption.
- **Financial risk**: Higher R&D spending and pending financing plans create cash flow uncertainty.

### Key quotes

> “I have great confidence in the entire Second Sight team and fully expect the organization not to miss a beat under Greg Williams' strong leadership as Chairman and acting CEO.” — Will McGuire

> “We completed the 12-month testing for the sixth and last subject in February 2020 and are pleased to report the results.”

> “We do think the overall trial size, and shall we say, will be driven by the safety endpoint, not the efficacy endpoint.” — Will McGuire

> “No, COVID-19 isn't really impacting it yet. This is just due to the ongoing negotiations with the agency over what their requirements are going to be.” — Pat Ryan

## Quarter one-liners

- **2019 Q4:** Second Sight reported positive 12‑month Orion study results, secured CE mark and conditional FDA approval for Argus 2s wearables, but pushed the IDE filing to H1 2021 and paused FLORA 20 validation due to COVID‑19.
- **2019 Q3:** Second Sight reports encouraging 12‑month Orion feasibility data, FDA endpoint agreement, ongoing R&D and reimbursement advocacy, while noting cash runway to Q2 2020 and financing still under review.
- **2019 Q2:** Second Sight reports positive 12‑month Orion feasibility results, advances FDA discussions and CMS reimbursement pathway, but faces declining Argus sales and regulatory timing uncertainty.
- **2019 Q1:** Second Sight accelerates its Orion platform after encouraging early feasibility data, while Argus II sales decline and the company reallocates resources and capital toward Orion amid regulatory and reimbursement uncertainties.
- **2018 Q4:** Second Sight reported modest Q4 sales, highlighted Orion feasibility progress, secured a $34.6M rights offering, and outlined 2019 goals while noting technical issues and reliance on FDA approvals.
- **2018 Q3:** Second Sight reports progress on Orion feasibility with five implants and home‑use training, Argus implants up 67%, a new $1.6 M NIH grant, but faces enrollment delays and pending FDA trial design.
- **2018 Q2:** Second Sight Q2 2018 call highlighted modest Argus implant revenue, progress on Orion feasibility and a strategic shift of capital toward Orion while managing cash and regulatory uncertainties.
- **2018 Q1:** Second Sight reports progress on Orion feasibility, Argus II implants and US demand, but notes cash runway limits and variability in international markets.

## Theme arcs

- **Capital allocation to Orion** (improving): Resources and financing increasingly directed to Orion platform
- **Regulatory uncertainty** (stable): Ongoing FDA endpoint and pathway discussions without resolution
- **Reimbursement variability** (deteriorating): CMS rates reduced and private payer coverage still uncertain
- **Cash runway/funding** (improving): Rights offering and non‑dilutive grants extended cash to 2020
- **Orion clinical enrollment** (deteriorating): Delays in sixth patient and enrollment gaps
- **Argus II sales** (deteriorating): Implant volumes declined and production suspended
- **Technical issues with Argus externals** (stable): Ongoing technical fixes affecting regulatory timing
- **COVID‑19 impact** (new): Paused FLORA 20 validation and potential trial delays
- **Market demand for Orion** (improving): Growing interest from key opinion leaders and US patient database

## Guidance path

2018 Q1:vague → 2018 Q2:vague → 2018 Q3:vague → 2018 Q4:vague → 2019 Q1:vague → 2019 Q2:vague → 2019 Q3:maintained → 2019 Q4:lowered

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/VANI`